Estropipate | CAS#7280-37-7 | Estrogen Receptor Agonist

MedKoo Cat#: 317789 | Name: Estropipate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Estropipate is a form of estrogen, an estrogen receptor agonist. It has several uses such as: Alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics, and treatment of prostate cancer and prevention of osteoporosis. Estropipate diffuses through the cell membrane and binds to and subsequently activates the nuclear estrogen receptor found in the reproductive tract, breast, pituitary, hypothalamus, liver, and bone. The activated complex binds to the estrogen response element on the DNA and activates the transcription of genes involved in the functioning of the female reproductive system and secondary sex characteristics.

Chemical Structure

Estropipate

CAS#7280-37-7

Theoretical Analysis

MedKoo Cat#: 317789

Name: Estropipate

CAS#: 7280-37-7

Chemical Formula: C22H32N2O5S

Exact Mass: 436.2032

Molecular Weight: 436.56

Elemental Analysis: C, 60.53; H, 7.39; N, 6.42; O, 18.32; S, 7.34

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 250.00	2 Weeks
10mg	USD 450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Estropipate; Piperazine estrone sulfate; Harmogen; Ogen; Piperazine estronesulfate; NSC 758912; NSC758912; NSC-758912

IUPAC/Chemical Name

piperazine (8R,9S,13S,14S)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl sulfate

InChi Key

HZEQBCVBILBTEP-ZFINNJDLSA-N

InChi Code

InChI=1S/C18H22O5S.C4H10N2/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;1-2-6-4-3-5-1/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);5-6H,1-4H2/t14-,15-,16+,18+;/m1./s1

SMILES Code

O=C1CC[C@@]2([H])[C@]3([H])CCC4=CC(OS(O)(=O)=O)=CC=C4[C@@]3([H])CC[C@@]21C.C5CNCCN5

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 436.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Bagdade JD, Subbaiah PV. Effects of estropipate treatment on plasma lipids and lipoprotein lipid composition in postmenopausal women. J Clin Endocrinol Metab. 1991 Feb;72(2):283-6. PubMed PMID: 1991799. 2: Zinser JR. Clarification for formulation of estropipate (Ogen). Am Fam Physician. 1994 Sep 1;50(3):542. PubMed PMID: 8067323. 3: Conaway E. Bioidentical hormones: an evidence-based review for primary care providers. J Am Osteopath Assoc. 2011 Mar;111(3):153-64. Review. PubMed PMID: 21464264. 4: Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJ. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med. 1981 Dec 31;305(27):1599-605. PubMed PMID: 7312007. 5: Gui C, Obaidat A, Chaguturu R, Hagenbuch B. Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics. 2010 Mar 1;4:1-8. doi: 10.2174/1875397301004010001. PubMed PMID: 20448812; PubMed Central PMCID: PMC2864424. 6: Klaiber EL, Broverman DM, Vogel W, Peterson LG, Snyder MB. Relationships of serum estradiol levels, menopausal duration, and mood during hormonal replacement therapy. Psychoneuroendocrinology. 1997 Oct;22(7):549-58. PubMed PMID: 9373888. 7: Greenberg DL, Payne ME, MacFall JR, Provenzale JM, Steffens DC, Krishnan RR. Differences in brain volumes among males and female hormone-therapy users and nonusers. Psychiatry Res. 2006 Oct 30;147(2-3):127-34. Epub 2006 Aug 28. PubMed PMID: 16935478. 8: Low LF, Anstey KJ, Jorm AF, Christensen H, Rodgers B. Hormone replacement therapy and cognition in an Australian representative sample aged 60-64 years. Maturitas. 2006 Apr 20;54(1):86-94. Epub 2005 Oct 12. PubMed PMID: 16226000. 9: Gutteridge DH, Holzherr ML, Retallack RW, Price RI, Will RK, Dhaliwal SS, Faulkner DL, Stewart GO, Stuckey BG, Prince RL, Criddle RA, Drury PJ, Tran L, Bhagat CI, Kent GN, Jamrozik K. A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density. Calcif Tissue Int. 2003 Jul;73(1):33-43. PubMed PMID: 14506952. 10: Alexandersen P, Byrjalsen I, Christiansen C. Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects. BJOG. 2000 Mar;107(3):356-64. PubMed PMID: 10740332. 11: Harvey PJ, Wing LM, Savage J, Molloy D. The effects of different types and doses of oestrogen replacement therapy on clinic and ambulatory blood pressure and the renin-angiotensin system in normotensive postmenopausal women. J Hypertens. 1999 Mar;17(3):405-11. PubMed PMID: 10100079. 12: Wen Y, Doyle MC, Harrison RF, Feely J. The effect of hormone replacement therapy on vitamin E status in postmenopausal women. Maturitas. 1997 Mar;26(2):121-4. PubMed PMID: 9089561. 13: Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS, LeBoff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. Hum Reprod. 1994 Sep;9(9):1618-25. PubMed PMID: 7836510. 14: Notelovitz M, Katz-Karp S, Jennings D, Lancaster J, Green EM, Stoll RW. Effect of cyclic estrone sulfate treatment on lipid profiles of postmenopausal women with elevated cholesterol levels. Obstet Gynecol. 1990 Jul;76(1):65-70. PubMed PMID: 2193271. 15: Aedo AR, Le Donne M, Landgren BM, Diczfalusy E. Effect of orally administered oestrogens on gonadotrophin levels in post-menopausal women. Maturitas. 1989 Jun;11(2):147-57. PubMed PMID: 2547138. 16: Wilson PD, Faragher B, Butler B, Bu'Lock D, Robinson EL, Brown AD. Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women. Br J Obstet Gynaecol. 1987 Jun;94(6):568-74. PubMed PMID: 3113475. 17: Wren B, Garrett D. The effect of low-dose piperazine oestrone sulphate and low-dose levonorgestrel on blood lipid levels in post-menopausal women. Maturitas. 1985 Jul;7(2):141-6. PubMed PMID: 3929024. 18: Varma TR, Everard D, Hole D. Effect of natural estrogen on the serum level of follicle-stimulating hormone (FSH), estradiol and estrone in post-menopausal women and its effect on endometrium. Acta Obstet Gynecol Scand. 1985;64(2):105-9. PubMed PMID: 2984875. 19: Wren BG, Routledge AD. The effect of type and dose of oestrogen on the blood pressure of post-menopausal women. Maturitas. 1983 Aug;5(2):135-42. PubMed PMID: 6314097. 20: Varma TR. Effect of oestrogen replacement therapy on blood coagulation factors in postmenopausal women. Int J Gynaecol Obstet. 1983 Aug;21(4):291-6. PubMed PMID: 6141083.

View History

Estrone